Jul. 17 at 11:44 AM
Citizens⬆️
$MDGL's PT and said -- We reiterate our Market Outperform rating and raise our risk-adjusted, DCF-derived PT on Madrigal Pharmaceuticals to
$739 from
$737.
$IVA $NVO ALGS VKTX
Citizens added—MDGL is reporting its 2Q financial results on July 30 at 8 a.m. ET. We lower our 2Q26 Rezdiffra estimate to
$354M from
$375M to be modestly above consensus of
$350M, still representing 14% Q/Q growth.
The increase in our PT is primarily a result of slightly lower GTN assumptions (including 37% this year vs. 39% previously).
We have not made any changes to our long-term conviction in Rezdiffraās peak sales potential, which we model as >
$6B before considering the F4 opportunity.
